Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs ProShares Ultra QQQ ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while ProShares Ultra QQQ ETF trades at $93. The key difference: ProShares Ultra QQQ ETF is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | QLD | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $339.75 | $100.53 |
52-Week Low | $241.71 | $57.16 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
QLD, the ProShares Ultra QQQ ETF, trades at $90.13, down 3.81% over 24 hours, reflecting a bearish technical signal with key support at $87. As a 2x daily leveraged ETF tracking the Nasdaq-100, it offers amplified exposure to large-cap tech stocks but carries inherent volatility risks. Recent news highlights its long-term performance, with over 10,000% total return since inception, though comparisons with 3x leveraged alternatives underscore drawdown vulnerabilities.
The outlook for QLD hinges on Nasdaq-100 momentum, with tech earnings and AI optimism as potential catalysts. However, leveraged decay and market volatility pose significant risks, making it suitable only for tactical, risk-tolerant investors. Current neutral oscillators suggest near-term consolidation, but bearish moving averages indicate downward pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
